NCT06093451View on ClinicalTrials.gov

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

PHASE4RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2024

Conditions
Schizophrenia AgitationSchizo Affective DisorderBipolar DisorderDexmedetomidine
Interventions
DRUG

Dexmedetomidine

Moderate agitation: 120 mcg Severe agitation: 180 mcg

DRUG

Lorazepam 2 MG/ML

2 mg

Trial Locations (1)

19125

RECRUITING

Temple University Episcopal Hospital, Philadelphia

Sponsors

Collaborators (1)

BioXcel Therapeutics Inc
All Listed Sponsors
collaborator

BioXcel Therapeutics Inc

INDUSTRY

lead

Temple University

OTHER